Navigation Links
Dosage of HIV drug may be ineffective for half of African-Americans
Date:8/27/2014

Many African-Americans may not be getting effective doses of the HIV drug maraviroc, a new study from Johns Hopkins suggests. The initial dosing studies, completed before the drug was licensed in 2007, included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body. The current study shows that people with maximum levels of the protein including nearly half of African-Americans end up with less maraviroc in their bodies compared to those who lack the protein even when given the same dose. A simple genetic test for the gene that makes the CYP3A5 protein could be used to determine what doses would achieve effective levels in individuals, the researchers say.

The results of the small study were published online on Aug. 12 in the journal Drug Metabolism and Disposition.

"Because African-Americans are disproportionately affected by HIV infection, it is doubly important that we get the dosing right," says Namandje Bumpus, Ph.D., an assistant professor of pharmacology and molecular sciences at the Johns Hopkins University School of Medicine.

CYP3A5 is a protein found in abundance in liver and intestinal cells. It adds an oxygen molecule to various drugs to make them more water-soluble so they can ultimately enter the urine and leave the body. Eighty to 90 percent of European-Americans have no CYP3A5, because they have inherited two dysfunctional copies of the CYP3A5 gene.

Normally, the absence of CYP3A5 is not noticeable; a very similar protein, CYP3A4, acts on most of the same drugs. But, for a few drugs, like maraviroc and the cancer drug vincristine, CYP3A5 seems to play a particularly prominent role in helping to remove them from the body. In those cases, the presence or absence of CYP3A5 would likely affect the amount of a drug in the bloodstream, the Johns Hopkins team predicted. And since 85 percent of participants in the maraviroc dosing study were European-Americans, who typically lack functional CYP3A5, the researchers surmised that the recommended dose for maraviroc could be too low for anyone with two functional copies of the gene including 45 percent of African-Americans.

To test this idea, the research team grouped 24 healthy volunteers according to how many functional copies of the CYP3A5 gene they had zero, one or two. They were each given a single dose of maraviroc in the recommended dose of 300 milligrams, and each participant's blood was taken at 10 time points over 32 hours.

At almost all time points, the concentrations of maraviroc were similar for the groups with zero or one functioning copies of CYP3A5 but were lower in those with two functioning copies. Compared to those with two poorly functioning copies of the gene, those with two functioning copies had a 41 percent lower concentration overall. Importantly, as a group, those with two functioning copies had an average concentration that was just above the lowest level determined to be effective against the virus. And four of the eight had individual average concentrations that dropped below that.

"The trend we saw was that the more functional CYP3A5 a person had, the faster maraviroc was processed and left the body, so the lower its concentration in the bloodstream," explains Bumpus. "What's nice is that, if a larger study confirms that we are underdosing this group, a simple genetic test prior to dosing decisions could rectify the situation."

She adds that this study highlights the importance of designing clinical trials in which the participants are as ethnically diverse as the population to be treated.


'/>"/>

Contact: Catherine Kolf
ckolf@jhmi.edu
443-287-2251
Johns Hopkins Medicine
Source:Eurekalert

Related biology news :

1. Automated CT dose-tracking software effectively monitors dosage in a clinical setting
2. MRSA drug dosage calculations found to be inaccurate for children over 10
3. Epilepsy drug dosage linked to specific birth defects
4. Optimal vitamin D dosage for infants uncertain
5. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
6. Lower dosage CT-guided lung biopsy protocol maintains quality, minimizes exposure
7. Genetic variation increases risk of kidney disease progression in African-Americans
8. Gene puts African-Americans at higher risk for kidney failure
9. Body mass index of low income African-Americans linked to proximity of fast food restaurants
10. Levels of hepatitis C virus higher among African-Americans and males
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
Breaking Biology News(10 mins):
(Date:2/25/2017)... ... February 25, 2017 , ... ... Trials in an ongoing effort to create meaningful change by increasing communication, ... research with emphasis on consumers and patients’ mental health well-being. , Both organizations ...
(Date:2/24/2017)... ... February 24, 2017 , ... A study recently published in ... ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, when compared to ... , Jake Lubinski, president of AxioMed, commented on the recent publication, stating, “We ...
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology ... the National Institute of Mental Health (NIMH) for the further advancement of the company’s ... technology and is expected to deliver therapeutic levels of olanzapine for a period ...
(Date:2/24/2017)... ... February 24, 2017 , ... Chef Jodi Abel has returned ... Making stops in several cities, she gained a number of delicious recipes and new ... a town in South Africa’s Western Cape province. It is internationally renowned for ...
Breaking Biology Technology: